Led by Senate Finance Committee Chair Ron Wyden, four Democratic senators on Wednesday outlined plans to reduce the costs of prescription drugs after President Led by Senate Finance Committee Chair Ron Wyden, four Democratic senators on Wednesday outlined plans to reduce the costs of prescription drugs after President

Senate Dems expose Trump's new 'fraud'

5 min read

Led by Senate Finance Committee Chair Ron Wyden, four Democratic senators on Wednesday outlined plans to reduce the costs of prescription drugs after President Donald Trump claimed he would do so—only to allow Big Pharma companies to delay negotiating lower prices and secure “zero commitments” from top executives on making lifesaving medications more affordable for millions of Americans.

“There is no greater fraud than Donald J. Trump when it comes to lower drug prices,” Wyden (D-Ore.) said. “Our doors are wide open to anybody who wants to take the bold next step forward on lowering drug costs for Americans.”

Along with a “flash report” on Trump’s “broken promises” regarding his pledge to bring drug prices down “to levels nobody ever thought was possible,” Wyden sent a Dear Colleague letter to Democratic senators regarding his committee’s plans to follow through with lowering costs.

“Finance Committee minority staff will dedicate substantial time and effort this year to developing the next generation of healthcare solutions that lower costs for American families,” Wyden wrote. “These solutions will rein in Big Pharma’s outrageous price increases, lower costs for consumers, guarantee predictability for patients, and reduce wasteful government spending that pads the profits of big corporations. Alongside the co-signers of this letter, I invite you to be a part of this bold vision.”

The letter, co-signed by Sens. Catherine Cortez Masto (D-Nev.), Peter Welch (D-Vt.), and Ruben Gallego (D-Ariz.), notes that “the only concrete drug pricing policy Trump enacted within the past year was a price hike for the biggest blockbuster cancer drugs on Earth, giving an $8.8 billion windfall to the pharmaceutical industry.”

In contrast, the senators wrote, the Senate Finance Committee will develop policies to incorporate international pricing models into the Medicare drug price negotiation framework, including by allowing Health and Human Services Secretary Robert F. Kennedy Jr. to consider international prices as a factor or penalize drugmakers when pricing for US customers exceeds international benchmarks.

“Democrats are determined to bring prices down, and we’re willing to work with anyone to find concrete ways to do it.”

The committee will also work to end Republican “blockbuster drug bailouts from negotiation,” like the ones included in the One Big Beautiful Bill Act that shielded several high-priced drugs—including the cancer drug Keytruda—from Medicare price negotiations.

“The Republican budget bill contained a nearly $9 billion sweetheart deal that benefits the biggest drug companies by delaying or exempting some lifesaving medications from negotiation,” reads the Democrats’ flash report.

Gallego said that “when Big Pharma gets richer off the back of a grandmother struggling to pay for cancer medication, the system is broken.”

“That’s what this is all about: Big Pharma execs sitting in their fancy corner offices profiting off of sick, working-class Americans,” the senator said. “We are not going to accept an America where millions of families live in fear of getting sick and needing to fill a prescription. We are going to fight and fight hard for a healthcare system that does what Donald Trump never did: actually lower costs for working families.”

The lawmakers emphasized that even if manufacturers are forced to lower drug prices, patients are not currently guaranteed to directly benefit, because as much as 45% of the $5.4 trillion the US spends on healthcare annually is “absorbed by middlemen such as insurers, pharmacy benefit managers (PBMs), and drug distributors.”

“Healthcare middlemen profit when drug costs are high because they make money off of drug margin or payments that are linked to the price of a drug, ripping off patients who pay more than they should. Medicare Part D and the patients it serves should stop footing the bill for inflated drug prices and instead pay for drugs in a more transparent manner that reduces middleman margin,” wrote the senators.

The Finance Committee will develop policies to eliminate abuses in the prescription drug supply chain including “egregious drug price markups,” and to ensure that patient cost-sharing on drugs more closely aligns with the costs to plans and PBMs.

Finally, the Democrats said they would work to fix the “unmitigated disaster” that Trump and Kennedy have been “for innovation and drug development,” as the administration has proposed slashing the National Institutes of Health budget by 40% and has cut off access to treatment for an estimated 74,000 patients who were enrolled in NIH clinical trials.

The Finance Committee, they said, plans to create new incentives for innovation and drug development, including through the tax code.

In their flash report, the Democrats wrote that while failing to force Big Pharma to the negotiating table to save money for Americans, Trump “has been parading Big Pharma executives through the White House, claiming to be cutting cost-saving deals with these corporations.”

“One look under the hood reveals the truth: Trump is giving them a pass on tariffs, while receiving zero commitments about how they will lower costs for taxpayers and patients,” they wrote. “Donald Trump is getting fleeced by Big Pharma CEOs, and Americans are going to foot the bill.”

Welch said that the president “loves to talk a big game and make promises to working families about lowering prescription drug prices. But in reality, his administration is handling this like a PR problem: They’ve got to keep moving and talking about it, but then do nothing to really address the crisis.”

“Democrats are determined to bring prices down, and we’re willing to work with anyone to find concrete ways to do it,” said Welch. “We’re going to lower healthcare costs and ensure everyone can access affordable, lifesaving, and pain-relieving medication.”

  • george conway
  • noam chomsky
  • civil war
  • Kayleigh mcenany
  • Melania trump
  • drudge report
  • paul krugman
  • Lindsey graham
  • Lincoln project
  • al franken bill maher
  • People of praise
  • Ivanka trump
  • eric trump
Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$3.726
$3.726$3.726
0.00%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

‘Big Short’ Michael Burry flags key levels on the Bitcoin chart

‘Big Short’ Michael Burry flags key levels on the Bitcoin chart

The post ‘Big Short’ Michael Burry flags key levels on the Bitcoin chart appeared on BitcoinEthereumNews.com. The famous ‘Big Short’ investor Michael Burry made
Share
BitcoinEthereumNews2026/02/05 21:54
Solana Price Prediction: SOL Tipped for 3x Boom While Little Pepe (LILPEPE) Gains 100x Speculation

Solana Price Prediction: SOL Tipped for 3x Boom While Little Pepe (LILPEPE) Gains 100x Speculation

Right now, the crypto community is buzzing with excitement as Solana (SOL) keeps gaining steam. Little Pepe (LILPEPE), a Layer 2 meme coin, is also on the rise in the market due to speculation about 100x returns. It’s clear that investors are watching a wide range of opportunities, given Solana’s impressive price hike over the
Share
Coinstats2025/09/19 04:30
New Zealand Dollar declines to near 0.5650 as dovish RBNZ overshadows US tariff relief

New Zealand Dollar declines to near 0.5650 as dovish RBNZ overshadows US tariff relief

The post New Zealand Dollar declines to near 0.5650 as dovish RBNZ overshadows US tariff relief appeared on BitcoinEthereumNews.com. The NZD/USD pair drifts lower to around 0.5655 during the Asian trading hours on Tuesday. The New Zealand Dollar (NZD) softens against the US Dollar (USD) amid an imminent rate cut from the Reserve Bank of New Zealand (RBNZ). Traders await the release of the US September Nonfarm Payrolls (NFP) report later on Thursday.  The RBNZ cut the Official Cash Rate (OCR) to 2.5% at its October meeting after a larger-than-expected 0.9% contraction in Gross Domestic Product (GDP) for the second quarter of 2025. A further reduction of 25 basis points (bps) to 2.25% is widely anticipated at the next meeting on November 26, 2025. The RBNZ has already delivered a series of rate cuts throughout 2025 in an attempt to stimulate a struggling economy.  The prospect of the RBNZ’s aggressive rate-cutting policy overshadowed the US decision to roll back tariffs on Kiwi exports. This, in turn, could exert some selling pressure on the NZD and acts as a tailwind for the pair. In the near term Meanwhile, US President Donald Trump lifted tariffs on more than 200 food products in response to rising US grocery prices. On Sunday, New Zealand welcomed the announcement that it would remove additional tariffs on a range of New Zealand agricultural products, including beef, offal, and kiwi fruit.  Trump removed tariffs on New Zealand exports on more than 200 food products, including beef, amid consumer concerns about rising US grocery prices. It is worth about NZ$2.21 billion ($1.25 billion) annually.  Hawkish remarks from Fed policymakers ahead of a deluge of US economic data spooked traders and could weigh on the USD. Kansas City Fed President Jeffery Schmid said on Friday that monetary policy should lean against demand growth, adding that current Fed policy is “modestly restrictive,” which he believes is appropriate.  New Zealand Dollar FAQs The New…
Share
BitcoinEthereumNews2025/11/18 10:59